Context Therapeutics (NASDAQ:CNTX - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). On average, analysts expect Context Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Context Therapeutics Trading Down 2.7%
Shares of CNTX traded down $0.02 during trading hours on Friday, reaching $0.71. The company had a trading volume of 119,312 shares, compared to its average volume of 196,248. The firm has a 50 day simple moving average of $0.68 and a 200-day simple moving average of $0.76. The company has a market capitalization of $63.69 million, a price-to-earnings ratio of -2.29 and a beta of 1.89. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.75.
Wall Street Analyst Weigh In
CNTX has been the subject of a number of research analyst reports. William Blair reiterated an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Piper Sandler reissued an "overweight" rating and issued a $4.00 price objective (down from $4.50) on shares of Context Therapeutics in a research note on Thursday, June 26th. Finally, D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $5.50.
View Our Latest Stock Analysis on CNTX
Insider Activity
In related news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were acquired at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the transaction, the chief financial officer owned 80,010 shares of the company's stock, valued at approximately $51,206.40. The trade was a 100.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martin A. Lehr purchased 100,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was acquired at an average price of $0.70 per share, for a total transaction of $70,000.00. Following the acquisition, the chief executive officer directly owned 920,190 shares of the company's stock, valued at $644,133. This trade represents a 12.19% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 160,010 shares of company stock worth $107,206 over the last ninety days. 2.80% of the stock is owned by corporate insiders.
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Featured Articles
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
